CureVac begins Phase III trial of Covid-19 vaccine candidate
The study aims to analyse the safety and immunogenicity of CVnCoV given as a two-dose schedule of 12µg. Credit: CureVac.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
